Development of AAV serotype-specific ELISAs using novel monoclonal antibodies

Journal of Virological Methods

Volumn 140, Issue 1-2, 2007, Pages 17-24

  Kuck, Dirk ^a   Kern, Andrea ^a   Kleinschmidt, Jürgen A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

AAV; Monoclonal antibodies; Serotype

Indexed keywords

CAPSID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ADK1A; MONOCLONAL ANTIBODY ADK1B; MONOCLONAL ANTIBODY ADK4; MONOCLONAL ANTIBODY ADK5A; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SEROTYPE; VIRUS CAPSID; VIRUS CHARACTERIZATION; VIRUS TITRATION;

ANTIBODIES, MONOCLONAL; CAPSID; CELL LINE; CROSS REACTIONS; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; PLASMIDS; SEROTYPING;

ADENO-ASSOCIATED VIRUS; MIRIDAE;

EID: 33846593292     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2006.10.005     Document Type: Article

References (40)

1. Bantel-Schaal U., Delius H., Schmidt R., and zur Hausen H. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J. Virol. 73 (1999) 939-947
2. Bleker S., Pawlita M., and Kleinschmidt J.A. Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J. Virol. 80 (2006) 810-820
3. Bowles D.E., and Samulski J.E.R.R.J. The Genus Dependovirus. In: Kerr J.R., Cotmore S.F., Bloom M.E., Linden R.M., and Parrish C.R. (Eds). Parvoviruses (2006), Edward Arnold, London
4. Chiorini J.A., Kim F., Yang L., and Kotin R.M. Cloning and characterization of adeno-associated virus type 5. J. Virol. 73 (1999) 1309-1319
5. Chiorini J.A., Yang L., Liu Y., Safer B., and Kotin R.M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71 (1997) 6823-6833
6. Dubielzig R., King J.A., Weger S., Kern A., and Kleinschmidt J.A. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J. Virol. 73 (1999) 8989-8998
7. Erles K., Sebokova P., and Schlehofer J.R. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59 (1999) 406-411
8. Fallaux F.J., Kranenburg O., Cramer S.J., Houweling A., Van Ormondt H., Hoeben R.C., and Van Der Eb A.J. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7 (1996) 215-222
9. Flotte T.R. Adeno-associated virus-based gene therapy for inherited disorders. Pediatr. Res. 58 (2005) 1143-1147
10. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., and Wilson J.M. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78 (2004) 6381-6388
11. Gao G., Vandenberghe L.H., and Wilson J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5 (2005) 285-297
12. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., and Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 11854-11859
13. Georg-Fries B., Biederlack S., Wolf J., and zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 134 (1984) 64-71
14. Grimm D., and Kay M.A. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3 (2003) 281-304
15. Grimm D., Kay M.A., and Kleinschmidt J.A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7 (2003) 839-850
16. Grimm D., Kern A., Pawlita M., Ferrari F., Samulski R., and Kleinschmidt J. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 6 (1999) 1322-1330
17. Grimm D., Kern A., Rittner K., and Kleinschmidt J.A. Novel tools for production and purification of recombinant adenoassociated virus vectors [in process citation]. Hum. Gene Ther. 9 (1998) 2745-2760
18. Halbert C.L., Miller A.D., McNamara S., Emerson J., Gibson R.L., Ramsey B., and Aitken M.L. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum. Gene Ther. 17 (2006) 440-447
19. Hunter L.A., and Samulski R.J. Colocalization of adeno-associated virus Rep and capsid proteins in the nuclei of infected cells. J. Virol. 66 (1992) 317-324
20. Kern A., Schmidt K., Leder C., Muller O.J., Wobus C.E., Bettinger K., Von der Lieth C.W., King J.A., and Kleinschmidt J.A. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 77 (2003) 11072-11081
21. King J.A., Dubielzig R., Grimm D., and Kleinschmidt J.A. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J. 20 (2001) 3282-3291
22. Kuck D., Lau T., Leuchs B., Kern A., Muller M., Gissmann L., and Kleinschmidt J.A. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J. Virol. 80 (2006) 2621-2630
23. Laughlin C.A., Tratschin J.D., Coon H., and Carter B.J. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 23 (1983) 65-73
24. Lux K., Goerlitz N., Schlemminger S., Perabo L., Goldnau D., Endell J., Leike K., Kofler D.M., Finke S., Hallek M., and Buning H. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking. J. Virol. 79 (2005) 11776-11787
25. Mori S., Wang L., Takeuchi T., and Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330 (2004) 375-383
26. Muramatsu S., Mizukami H., Young N.S., and Brown K.E. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 221 (1996) 208-217
27. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
28. Pear W.S., Nolan G.P., Scott M.L., and Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8392-8396
29. Rohde V., Erles K., Sattler H.P., Derouet H., Wullich B., and Schlehofer J.R. Detection of adeno-associated virus in human semen: does viral infection play a role in the pathogenesis of male infertility?. Fertil. Steril. 72 (1999) 814-816
30. Ruffing M., Zentgraf H., and Kleinschmidt J.A. Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J. Virol. 66 (1992) 6922-6930
31. Rutledge E.A., Halbert C.L., and Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72 (1998) 309-319
32. Samulski R.J., Berns K.I., Tan M., and Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 2077-2081
33. Strickler H.D., Viscidi R., Escoffery C., Rattray C., Kotloff K.L., Goldberg J., Manns A., Rabkin C., Daniel R., Hanchard B., Brown C., Hutchinson M., Zanizer D., Palefsky J., Burk R.D., Cranston B., Clayman B., and Shah K.V. Adeno-associated virus and development of cervical neoplasia. J. Med. Virol. 59 (1999) 60-65
34. Sun J.Y., Anand-Jawa V., Chatterjee S., and Wong K.K. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 10 (2003) 964-976
35. Walz C.M., Nakamura M., Fukunaga T., Jasiewicz Y., Edler L., Schlehofer J.R., and Tanaka Y. Reduced prevalence of serum antibodies against adeno-associated virus type 2 in patients with adult T-cell leukaemia lymphoma. J. Med. Virol. 65 (2001) 185-189
36. Wistuba A., Kern A., Weger S., Grimm D., and Kleinschmidt J.A. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J. Virol. 71 (1997) 1341-1352
37. Wistuba A., Weger S., Kern A., and Kleinschmidt J.A. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J. Virol. 69 (1995) 5311-5319
38. Wobus C.E., Hugle-Dorr B., Girod A., Petersen G., Hallek M., and Kleinschmidt J.A. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74 (2000) 9281-9293
39. Xiao W., Chirmule N., Berta S.C., McCullough B., Gao G., and Wilson J.M. Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73 (1999) 3994-4003
40. Xiao W., Warrington Jr. K.H., Hearing P., Hughes J., and Muzyczka N. Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J. Virol. 76 (2002) 11505-11517